`
`
`
`
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF DELAWARE
`
`
`FRESENIUS KABI USA, LLC,
`
`
`
`
`
`v.
`
`Plaintiff,
`
`CLARIS LIFESCIENCES LTD.
`and CLARIS LIFESCIENCES INC.,
`Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Civil Action No. _________
`
`COMPLAINT
`
`Fresenius Kabi USA, LLC (“Fresenius”) brings this action for patent infringement
`
`against Defendants Claris Lifesciences Ltd. (“Claris Ltd.”) and Claris Lifesciences Inc. (“Claris
`
`Inc.”) (collectively, “Claris” or “Defendants”).
`
`1.
`
`This is an action by Fresenius against Defendants for infringement of United
`
`States Patent No. 8,476,010 (“the ʼ010 patent”). This action arises out of Claris’s filing of an
`
`Abbreviated New Drug Application (“ANDA”) seeking approval by the United States Food and
`
`Drug Administration (“FDA”) to sell generic versions of Diprivan®, an innovative intravenously
`
`administered sedative and anesthetic, prior to the expiration of the ʼ010 patent.
`
`Fresenius
`
`THE PARTIES
`
`2.
`
`Fresenius is a Delaware limited liability company with its principal place of
`
`business at Three Corporate Drive, Lake Zurich, Illinois 60047. Fresenius Kabi USA, LLC was
`
`formerly known as APP Pharmaceuticals, LLC.
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 2 of 12 PageID #: 2
`
`Defendants
`
`3.
`
`Upon information and belief, Claris Ltd. is a corporation organized and existing
`
`under the laws of India, with its principal place of business at Nr. Parimal Crossing, Ellisbridge,
`
`Ahmedabad, 380006, India.
`
`4.
`
`Upon information and belief, Claris Inc. is a corporation organized and existing
`
`under the laws of New Jersey with its principal place of business at 1445 US Highway 130,
`
`North Brunswick, NJ 08902.
`
`5.
`
`Upon information and belief, Claris Inc. is a wholly-owned subsidiary of and is
`
`controlled by Claris Ltd.
`
`6.
`
`Upon information and belief, both Claris Ltd. and Claris Inc. submitted,
`
`collaborated and/or acted in concert in the preparation or submission of ANDA No. 203421 (the
`
`“Claris ANDA”).
`
`Subject Matter Jurisdiction
`
`JURISDICTION AND VENUE
`
`7.
`
`8.
`
`This action for patent infringement arises under 35 U.S.C. § 271.
`
`This Court has jurisdiction over the subject matter of this action pursuant to 28
`
`U.S.C. §§ 1331, 1338(a), 2201, and 2202.
`
`Personal Jurisdiction Over Defendants
`
`9.
`
`10.
`
`Upon information and belief, this Court has personal jurisdiction over Claris Ltd.
`
`Upon information and belief, Claris Ltd., through its wholly-owned subsidiary
`
`and agent Claris Inc., markets, distributes and/or sells generic drugs throughout the United States
`
`and within the State of Delaware.
`
`
`
`2
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 3 of 12 PageID #: 3
`
`11.
`
`Upon information and belief, Claris Ltd. has engaged in and maintained
`
`systematic and continuous business contacts within the State of Delaware, and has purposefully
`
`availed itself of the benefits and protections of the laws of Delaware, rendering it at home in
`
`Delaware.
`
`12.
`
`Upon information and belief, Claris Ltd. routinely files ANDAs in the United
`
`States and markets a numerous generic injectable pharmaceutical products, including, inter alia,
`
`ciprofloxacin, fluconazole, furosemide, levofloxacin, metoprolol tartrate, metronidazole,
`
`norepinephrine bitartrate, and ondansetron hydrochloride.
`
`13.
`
`Upon information and belief, Claris Ltd. has agreements with pharmaceutical
`
`retailers, wholesalers or distributors providing for the distribution of its products in the State of
`
`Delaware, including, inter alia, ciprofloxacin, fluconazole, furosemide, levofloxacin, metoprolol
`
`tartrate, metronidazole, norepinephrine bitartrate, and ondansetron hydrochloride.
`
`14.
`
`Upon information and belief, Claris Ltd. has committed, or aided, abetted,
`
`contributed to and/or participated in the commission of the tortious action of patent infringement
`
`that has led to foreseeable harm and injury to Fresenius, which manufactures Diprivan®, for sale
`
`and use throughout the United States, including the State of Delaware.
`
`15.
`
`Upon information and belief, Claris Ltd. has applied for FDA approval to market
`
`and sell a generic version of Diprivan® throughout the United States, including in Delaware.
`
`16.
`
`On November 4, 2014, Claris Ltd. sent a letter to Fresenius, a Delaware Limited
`
`Liability Company, stating that it had filed ANDA No. 203421 seeking FDA approval to market
`
`a generic Diprivan® product prior to the expiration of the ’010 patent (the “Claris Notice
`
`Letter”).
`
`
`
`3
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 4 of 12 PageID #: 4
`
`17.
`
`Upon information and belief, Claris Ltd. will market, sell, and offer for sale its
`
`proposed generic version of Diprivan® in the State of Delaware following FDA approval of that
`
`product.
`
`18.
`
`Upon information and belief, as a result of Claris Ltd.’s marketing, selling, or
`
`offering for sale of its generic version of Diprivan® in the State of Delaware, Fresenius will lose
`
`sales of Diprivan® and be injured in the State of Delaware.
`
`19.
`
`Upon information and belief, Claris Ltd.’s systematic and continuous business
`
`contacts within Delaware render it at home in Delaware.
`
`20.
`
`Upon information and belief, this Court has personal jurisdiction over Claris Ltd.
`
`for the reasons stated herein, including, inter alia, Claris Ltd.’s activities in the forum, activities
`
`directed at the forum, significant contacts with the forum, and consent, all of which render Claris
`
`Ltd. at home in the forum.
`
`21.
`
`This Court also has personal jurisdiction over Claris Ltd. under Federal Rule of
`
`Civil Procedure 4(k)(2).
`
`22.
`
`23.
`
`Upon information and belief, this Court has personal jurisdiction over Claris Inc.
`
`Upon information and belief, Claris Inc., as an agent of Claris Ltd., markets,
`
`distributes and/or sells generic drugs throughout the United States and within the State of
`
`Delaware.
`
`24.
`
`Upon information and belief, Claris Inc. has engaged in and maintained
`
`systematic and continuous business contacts within the State of Delaware, and has purposefully
`
`availed itself of the benefits and protections of the laws of Delaware.
`
`
`
`4
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 5 of 12 PageID #: 5
`
`25.
`
`Upon information and belief, Claris Inc. collaborated and/or acted in concert with
`
`Claris Ltd. to apply for FDA approval to market and sell a generic version of Diprivan®
`
`throughout the United States, including in Delaware.
`
`26.
`
`Upon information and belief, Claris Inc. collaborated in the decision to send the
`
`Claris Notice Letter to Fresenius, a Delaware Limited Liability Company.
`
`27.
`
`Upon information and belief, Claris Inc. will act as the agent of Claris Ltd. by
`
`marketing, selling, and/or offering for sale a generic version of Diprivan® in the State of
`
`Delaware on Claris Ltd.’s behalf following FDA approval of that product.
`
`28.
`
`Upon information and belief, Claris Inc. has committed, or aided, abetted,
`
`contributed to and/or participated in the commission of the tortious action of patent infringement
`
`that has led to foreseeable harm and injury to Fresenius, which manufactures Diprivan®, for sale
`
`and use throughout the United States, including the State of Delaware.
`
`29.
`
`Upon information and belief, Claris Inc.’s systematic and continuous business
`
`contacts within Delaware render it at home in Delaware.
`
`30.
`
`Upon information and belief, this Court has personal jurisdiction over Claris Inc.
`
`for the reasons stated herein, including by virtue of Claris Inc.’s activities in the forum, activities
`
`directed at the forum, and significant contacts with the forum, all of which render Claris Inc. at
`
`home in the forum.
`
`Venue
`
`31.
`
`Venue is proper in this Judicial District under 28 U.S.C. § 1391 and 1400(b).
`
`The Patent-in-Suit: United States Patent No. 8,476,010
`
`BACKGROUND
`
`
`
`5
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 6 of 12 PageID #: 6
`
`32.
`
`The ʼ010 patent, entitled “Propofol Formulations with Non-Reactive Container
`
`Closures,” was duly and lawfully issued on July 2, 2013 to inventors Neil P. Desai, Andrew
`
`Yang, and Sherry Xiaopei Ci. The named inventors assigned the ʼ010 patent to APP
`
`Pharmaceuticals, LLC, which later changed its name to Fresenius Kabi USA, LLC.
`
`Accordingly, Fresenius is the owner of all rights, title, and interest in the ʼ010 patent. The ʼ010
`
`patent is listed in the FDA publication “Approved Drug Products with Therapeutic Equivalence
`
`Evaluations,” commonly referred to as “The Orange Book” (“Orange Book”) with respect to
`
`Diprivan®. The ʼ010 patent will expire on June 1, 2025. A true and accurate copy of the ʼ010
`
`patent is attached hereto as Exhibit A.
`
`The Diprivan® Drug Product
`
`33.
`
`Fresenius currently sells, promotes, distributes, and markets Diprivan® (propofol)
`
`injectable emulsion in the United States.
`
`34.
`
`Diprivan® is indicated, generally speaking, for the induction and maintenance of
`
`general anesthesia and sedation in certain patient populations.
`
`35.
`
`Fresenius holds an approved New Drug Application (“NDA”) No. 19627 under
`
`Section 505(b) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a) in connection
`
`with the Diprivan® 1% (propofol) injectable emulsion product containing 10 mg propofol per 1
`
`ml of emulsion.
`
`The Claris ANDA
`
`
`
`6
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 7 of 12 PageID #: 7
`
`36.
`
`Claris filed with the FDA an ANDA under 21 U.S.C. § 355(j) seeking approval to
`
`manufacture, use, offer for sale, sell in and import into the United States a propofol injectable
`
`emulsion containing 10mg propofol per 1 ml of emulsion formulation that Claris asserts is a
`
`generic copy of Diprivan® (“Claris’s generic Diprivan® products”) prior to the expiration of the
`
`ʼ010 patent.
`
`37.
`
`38.
`
`The FDA assigned the Claris ANDA the number 203421.
`
`Claris filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a
`
`certification alleging that the claims of the ʼ010 patent are invalid, unenforceable and/or would
`
`not be infringed by the manufacture, use, importation, sale or offer for sale of Claris’s generic
`
`Diprivan® products (“Claris’s Paragraph IV Certification”). Claris notified Fresenius of this
`
`certification, in a letter dated November 4, 2014 sent by U.S. Mail.
`
`39.
`
`In the Claris Notice Letter, Claris offered Fresenius confidential access to ANDA
`
`No. 203421 on terms and conditions set forth in an attached “Offer of Confidential Access”
`
`(“OCA”). The OCA provided by Claris contained various terms and conditions, several of
`
`which went above and beyond protections typically afforded in a protective order. For instance,
`
`the initial Claris OCA limited the number of Fresenius in-house counsel who could access the
`
`Claris ANDA and did not provide for access by in-house counsel’s staff.
`
`40.
`
`On November 10, 2014, Fresenius provided Claris with a revised draft of the
`
`OCA.
`
`41.
`
`On November 21, 2014, Claris’s counsel communicated to Teva that Claris would
`
`not consider Fresenius’s proposed changes to the OCA.
`
`
`
`7
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 8 of 12 PageID #: 8
`
`42.
`
`Given the 45-day statutory deadline to file suit set forth in 21 U.S.C.
`
`§ 355(j)(5)(B)(iii) and Claris’s refusal to negotiate regarding an OCA, Fresenius turns to the
`
`judicial process and the aid of discovery to obtain, under appropriate judicial safeguards, such
`
`information as is required to further confirm their allegations of infringement and to present to
`
`the Court evidence that Claris’s generic Diprivan® products fall within the scope of one or more
`
`claims of the ’010 patent.
`
`COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,476,010 BY
`DEFENDANTS
`
`43.
`
`The allegations of paragraphs 1-42 are realleged and incorporated herein by
`
`reference.
`
`44.
`
`The use of Claris’s generic Diprivan® products is covered by one or more claims
`
`of the ʼ010 patent.
`
`45.
`
`The commercial manufacture, use, offer for sale, sale, marketing, distribution,
`
`and/or importation of Claris’s generic Diprivan® products would infringe one or more claims of
`
`the ʼ010 patent.
`
`46.
`
`Defendants have infringed the ʼ010 patent by submitting and maintaining the
`
`Claris ANDA before the FDA seeking approval to market Claris’s generic Diprivan® products
`
`containing propofol before the expiration of the ʼ010 patent.
`
`47.
`
`Upon information and belief, Defendants acted in concert and actively and
`
`knowingly caused to be submitted, assisted with, participated in, encouraged, contributed to,
`
`aided and abetted, and/or directed the submission and maintenance of the Claris ANDA to the
`
`FDA.
`
`
`
`8
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 9 of 12 PageID #: 9
`
`48.
`
`Defendants induced the infringement of the ʼ010 patent by actively and
`
`knowingly aiding and abetting the preparation, submission, and maintenance of the Claris
`
`ANDA with the Paragraph IV Certification and in the preparation to sell Claris’s generic
`
`Diprivan® product in the United States.
`
`49.
`
`Defendants were aware of the ʼ010 patent when engaging in these knowing and
`
`purposeful activities and were aware that filing the Claris ANDA with the Paragraph IV
`
`Certification with respect to the ʼ010 patent constituted an act of infringement of the ’010 patent.
`
`50.
`
`Use of Claris’s generic Diprivan® products in accordance with and as directed by
`
`Claris’s proposed labeling for that product would infringe one or more claims of the ʼ010 patent.
`
`51.
`
`Upon information and belief, Defendants intend to engage in the manufacture,
`
`use, offer for sale, sale, marketing, distribution, and/or importation of Claris’s generic Diprivan®
`
`products with its proposed labeling immediately and imminently upon approval of the Claris
`
`ANDA.
`
`52.
`
`Upon information and belief, Defendants plan and intend to, and will, actively
`
`induce infringement of the ʼ010 patent when the Claris ANDA is approved, and plan and intend
`
`to, and will, do so immediately and imminently upon approval.
`
`53.
`
`Upon information and belief, Defendants know that Claris’s generic Diprivan®
`
`product and the proposed labeling for Claris’s generic Diprivan® product is especially made or
`
`adapted for use in infringing the ʼ010 patent and that Claris’s generic Diprivan® product and the
`
`proposed labeling are not suitable for substantial noninfringing use. Upon information and
`
`belief, Defendants plan and intend to, and will, contribute to the infringement of the ʼ010 patent
`
`immediately and imminently upon approval of the Claris ANDA.
`
`
`
`9
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 10 of 12 PageID #: 10
`
`54.
`
`The foregoing actions by Defendants constitute and/or would constitute
`
`infringement of the ʼ010 patent, active inducement of infringement of the ʼ010 patent and/or
`
`contribution to the infringement by others of the ʼ010 patent.
`
`55.
`
`Upon information and belief, Defendants acted without a reasonable basis for
`
`believing that they would not be liable for infringing the ʼ010 patent, actively inducing
`
`infringement of the ʼ010 patent, and/or contributing to the infringement by others of the ʼ010
`
`patent.
`
`56.
`
`Fresenius will be substantially and irreparably harmed by Defendants’ infringing
`
`activities unless the Court enjoins those activities. Fresenius will have no adequate remedy at
`
`law if Defendants are not enjoined from the commercial manufacture, use, offer to sell, sale in,
`
`and importation into the United States of Claris’s generic Diprivan® products.
`
`57.
`
`Defendants’ activities render this case an exceptional one, and Fresenius is
`
`entitled to an award of its reasonable attorney fees under 35 U.S.C. § 285.
`
`PRAYER FOR RELIEF
`
`
`
`WHEREFORE, Fresenius respectfully requests the following relief:
`
`a.
`
`A judgment that Defendants’ submission of Claris ANDA No. 203421 infringes
`
`one or more claims of the ʼ010 patent and that the making, using, offering to sell, or selling in the
`
`United States, or importing into the United States of Claris’s generic Diprivan® products prior to
`
`the expiration of the ʼ010 patent will infringe, actively induce infringement, and/or contribute to
`
`the infringement of one or more claims of the patent;
`
`
`
`10
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 11 of 12 PageID #: 11
`
`b.
`
`An Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of
`
`any FDA approval of Claris ANDA No. 203421 seeking approval to manufacture, use, offer for
`
`sale, sell in and import into the United States a propofol injectable emulsion containing 10mg
`
`propofol per 1 ml of emulsion formulation, or any product or compound the use of which
`
`infringes the ʼ010 patent, shall be a date that is not earlier than the expiration of the patent;
`
`c.
`
`An Order permanently enjoining Defendants and all persons acting in concert
`
`with Defendants from commercially manufacturing, using, offering for sale, selling, marketing,
`
`distributing, or importing Claris’s generic Diprivan® products, or any other product or compound
`
`the use of which infringes the ʼ010 patent, or inducing or contributing to the infringement of the
`
`ʼ010 patent until after the expiration of the patent;
`
`d.
`
`An Order enjoining Defendants and all persons acting in concert with Defendants
`
`from seeking, obtaining, or maintaining approval of the Claris ANDA No. 203421 before the
`
`expiration of the ʼ010 patent;
`
`e.
`
`An award of Plaintiff’s damages or other monetary relief to compensate Plaintiff
`
`if Defendants engage in the commercial manufacture, use, offer to sell, sale or marketing or
`
`distribution in, or importation into the United States of Defendants’ generic Diprivan® products,
`
`or any product or compound the use of which infringes the ʼ010 patent, or the inducement or
`
`contribution of the foregoing, prior to the expiration of the patent in accordance with 35 U.S.C. §
`
`271(e)(4)(C);
`
`f.
`
`A judgment that this is an exceptional case and awarding Plaintiff its attorneys’
`
`fees under 35 U.S.C. § 285;
`
`g.
`
`An award of Plaintiff’s reasonable costs and expenses in this action; and
`
`
`
`11
`
`
`
`Case 1:14-cv-01498-RGA Document 1 Filed 12/19/14 Page 12 of 12 PageID #: 12
`
`h.
`
`An award of any further and additional relief to Plaintiff as this Court deems just
`
`and proper.
`
`Respectfully submitted,
`
`FARNAN LLP
`
`
`/s/ Brian E. Farnan
`Brian Farnan(Bar No. 4089)
`919 North Market Street
`12th Floor
`Wilmington, DE 19801
`Phone: 302-777-0300
`Fax: 302-777-0301
`bfarnan@farnanlaw.com
`
`
`
`
`
`
`
`Attorneys for Plaintiff
`Fresenius Kabi USA, LLC
`
`
`
`Dated: December 19, 2014
`
`
`
`Of Counsel:
`
`Daryl L. Wiesen
`John T. Bennett
`Sundar Subramanyam
`Srikanth Reddy
`Jennifer L. Ford
`Todd Marabella
`GOODWIN PROCTER LLP
`Exchange Place
`53 State Street
`Boston, MA 02109
`(617) 570-1000
`(617) 523-1231 (fax)
`DWiesen@goodwinprocter.com
`
`JBennett@goodwinprocter.com
`SSubramanyam@goodwinprocter.com
`SReddy@goodwinprocter.com
`JFord@goodwinprocter.com
`TMarabella@goodwinprocter.com
`
`
`
`
`
`12